Company intelligence / Profile preview
Lento Bio
Syracuse, New York, United Stateslentobio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lento Bio is a preclinical biotech company developing small molecule eyedrops aimed at treating presbyopia by increasing lens flexibility. The lead program targets molecular damage—specifically glycation—that causes age-related stiffening of the ocular lens. No clinical results are available yet as the programs are in preclinical development.
- Therapeutic areas
- OtherOphthalmology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Florida State University (official academic collaboration)
Beyond the preview
Go deeper on Lento Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lento Bio.